Skip to content

Role of Kabasura Kudineer in managing Covid patients

Effectiveness of Kabasura Kudineer in Management of Asymptomatic, Mild to Moderate cases of COVID -19 : An Open Label, Single Blind, Pilot Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032952
Enrollment
100
Registered
2021-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Kabasura Kudineer: asymptomatic and mild cases: 2 tablet a day orally for period of 15 days as standalone moderate case : 2 tablet a day orally for period of 15 days with standard ther

Sponsors

Sri Sri tatva advanced research institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 18 to 55 years, both male & female Asymptomatic, mild to moderate confirmed cases of covid19 infection as per GOI definition Reported to OPD within 3 days of onset of symptoms Willing to take ayush treatment

Exclusion criteria

Exclusion criteria: patients not willing to give consent or participate in the clinical trial patients with co-morbidities like known case of hypertension , diabetes, heart diseases thyroid disorders,liver or renal diseases,moderate to severe anemia, blood related disorders etc Patients with associated co-morbidities like known case of hypertension, type 2 or type 1 diabetes or chronic or acute renal failure, thyroid disorder, respiratory diseases (asthama, copd ) renal diseases. Baseline investigation CBC, LFT, KFT, RBS shows abnormalities patients on immuno-suppressive therapy pregnant women or lactating mothers undergone major surgery in recent 6 months or hospitalized for more than 3 days for any condition.

Design outcomes

Primary

MeasureTime frame
a.Time needed for improvement and relief in sign and symptoms individually and term of Pandemic Respiratory Infection Emergency System Triage (PRIEST) score b.Variation in immunity markers ( IL6, CRP) c.Time needed for sero-conversion d.Duration and events during hospital / home stay e.Time for clinical recovery in terms of rtpcr and viral clearanceTimepoint: at baseline, 5 days, 10 days and 15 days , 21-28 days

Secondary

MeasureTime frame
a.Residual symptoms if any from 21 days to 3 months of follow up b.Effect on mental health as measured by DASS 21 (hindi version open source)Timepoint: 3 month

Countries

India

Contacts

Public ContactDr Meenakshi Khapre

AIIMS Rishikesh

drmeenaxi15@ymail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026